Lck kinase inhibitors (Boehringer)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameLck kinase inhibitors (Boehringer)
Drug Alias NameBIRA-0596ULL-10033BIRA-802
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase LCK inhibitorsImmunosuppressants
TargetsTyrosine-protein kinase LCK
Therapy Area/IndicationsRejection of organ transplantationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim Corp
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A